Your browser doesn't support javascript.
loading
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Guidi, Monia; Mercier, Thomas; Aouri, Manel; Decosterd, Laurent A; Csajka, Chantal; Ogutu, Bernhards; Carn, Gwénaëlle; Kiechel, Jean-René.
Afiliação
  • Guidi M; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
  • Mercier T; Laboratory and Service of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
  • Aouri M; Laboratory and Service of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
  • Decosterd LA; Laboratory and Service of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
  • Csajka C; Laboratory and Service of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
  • Ogutu B; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
  • Carn G; Laboratory and Service of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
  • Kiechel JR; Kenya Medical Research Institute, Kisumu, Kenya.
Malar J ; 18(1): 139, 2019 Apr 18.
Article em En | MEDLINE | ID: mdl-30999915
ABSTRACT

BACKGROUND:

The World Health Organization (WHO) recommends combinations of an artemisinin derivative plus an anti-malarial drug of longer half-life as treatment options for uncomplicated Plasmodium falciparum infections. In Africa, artesunate-mefloquine (ASMQ) is an infrequently used artemisinin-based combination therapy (ACT) because of perceived poor tolerance to mefloquine. However, the WHO has recommended reconsideration of the use of ASMQ in Africa. In this large clinical study, the pharmacokinetics (PK) of a fixed dose combination of ASMQ was investigated in an African paediatric population to support dosing recommendations used in Southeast Asia and South America.

METHODS:

Among the 472 paediatric patients aged 6-59 months from six African centres included in the large clinical trial, a subset of 50 Kenyan children underwent intensive sampling to develop AS, its metabolite dihydroartemisinin (DHA) and MQ PK models. The final MQ PK model was validated using sparse data collected in the remaining participants (NONMEM®). The doses were one or two tablets containing 25/55 mg AS/MQ administered once a day for 3 days according to patients' age. A sensitive LC-MS/MS method was used to quantify AS, DHA and MQ concentrations in plasma. An attempt was made to investigate the relationship between the absence/presence of malaria recrudescence and MQ area under the curve (AUC) using logistic regression.

RESULTS:

AS/DHA concentration-time profiles were best described using a one-compartment model for both compounds with irreversible AS conversion into DHA. AS/DHA PK were characterized by a significant degree of variability. Body weight affected DHA PK parameters. MQ PK was characterized by a two-compartment model and a large degree of variability. Allometric scaling of MQ clearances and volumes of distribution was used to depict the relationship between MQ PK and body weight. No association was found between the model predicted AUC and appearance of recrudescence.

CONCLUSIONS:

The population pharmacokinetic models developed for both AS/DHA and MQ showed a large variability in drug exposure in the investigated African paediatric population. The largest contributor to this variability was body weight, which is accommodated for by the ASMQ fixed dose combination (FDC) dosing recommendation. Besides body weight considerations, there is no indication that the dosage should be modified in children with malaria compared to adults. Trial registration Pan African Clinical Trials Registry PACTR201202000278282 registration date 2011/02/16.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mefloquina / Malária Falciparum / Artesunato / Antimaláricos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limite: Child, preschool / Female / Humans / Infant / Male País/Região como assunto: Africa Idioma: En Revista: Malar J Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mefloquina / Malária Falciparum / Artesunato / Antimaláricos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies Limite: Child, preschool / Female / Humans / Infant / Male País/Região como assunto: Africa Idioma: En Revista: Malar J Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Suíça